Free Trial

Apogee Therapeutics (APGE) Insider Trading & Ownership

Apogee Therapeutics logo
$48.09 +0.88 (+1.86%)
(As of 12/17/2024 ET)

Apogee Therapeutics (NASDAQ:APGE) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
36.10%
Number Of
Insiders Buying
(Last 12 Months)
1
Amount Of
Insider Buying
(Last 12 Months)
$990,800.00
Number Of
Insiders Selling
(Last 12 Months)
3
Amount Of
Insider Selling
(Last 12 Months)
$10.35 M
Get APGE Insider Trade Alerts

Want to know when executives and insiders are buying or selling Apogee Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

APGE Insider Buying and Selling by Quarter

Apogee Therapeutics Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/12/2024Mark C MckennaDirectorBuy20,000$49.54$990,800.00  
12/11/2024Carl DambkowskiInsiderSell4,540$48.76$221,370.40  
12/4/2024Carl DambkowskiInsiderSell6,665$46.07$307,056.55  
12/4/2024Michael Thomas HendersonCEOSell15,000$46.58$698,700.00  
11/6/2024Carl DambkowskiInsiderSell6,665$59.12$394,034.80  
11/6/2024Michael Thomas HendersonCEOSell15,000$59.22$888,300.00  
10/2/2024Carl DambkowskiInsiderSell6,665$56.26$374,972.90  
10/2/2024Michael Thomas HendersonCEOSell40,000$56.23$2,249,200.00  
9/4/2024Carl DambkowskiInsiderSell6,665$47.56$316,987.40  
9/4/2024Michael Thomas HendersonCEOSell40,000$47.62$1,904,800.00  
8/23/2024Jane HendersonCFOSell6,000$48.26$289,560.00  
8/7/2024Carl DambkowskiInsiderSell7,335$40.67$298,314.45  
8/7/2024Michael Thomas HendersonCEOSell40,000$40.62$1,624,800.00  
7/5/2024Michael Thomas HendersonCEOSell15,000$37.26$558,900.00  
7/3/2024Carl DambkowskiInsiderSell5,995$37.60$225,412.00  
(Data available from 1/1/2013 forward)

APGE Insider Trading Activity - Frequently Asked Questions

The list of insiders at Apogee Therapeutics includes Carl Dambkowski, Jane Henderson, Mark C Mckenna, Michael Thomas Henderson, and Nimish P Shah. Learn more on insiders at APGE.

36.10% of Apogee Therapeutics stock is owned by insiders. Learn more on APGE's insider holdings.

The following insiders have purchased APGE shares in the last 24 months: Mark C Mckenna ($990,800.00), and Nimish P Shah ($29,750,000.00).

Insiders have purchased a total of 1,770,000 APGE shares in the last 24 months for a total of $30,740,800.00 bought.

The following insiders have sold APGE shares in the last 24 months: Carl Dambkowski ($2,138,148.50), Jane Henderson ($289,560.00), and Michael Thomas Henderson ($7,924,700.00).

Insiders have sold a total of 215,530 Apogee Therapeutics shares in the last 24 months for a total of $10,352,408.50 sold.

Apogee Therapeutics Key Executives

  • Dr. Michael Thomas Henderson M.D.Dr. Michael Thomas Henderson M.D. (Age 34)
    CEO & Director
    Compensation: $1.17M
    6 recent trades
  • Ms. Jane Pritchett V. Henderson (Age 58)
    Chief Financial Officer
    Compensation: $843.64k
  • Dr. Carl Linden Dambkowski M.D. (Age 38)
    Chief Medical Officer
    Compensation: $870.83k
  • Ms. Noel Kurdi
    Vice President of Investor Relations
  • Mr. Matthew Batters J.D. (Age 48)
    Chief Legal Officer & Corporate Secretary
  • Ms. Emily Cox
    VP & Head of People
  • Dr. Rebecca Dabora Ph.D. (Age 64)
    Chief Development Officer
  • Ms. Wendy Aspden-Curran
    Senior Vice President of Clinical Operations
  • Dr. Drew Badger Ph.D.
    Senior VP and Head of Regulatory Affairs & Toxicology
  • Ms. Monica Forbes (Age 48)
    Senior Vice President of Finance


This page (NASDAQ:APGE) was last updated on 12/18/2024 by MarketBeat.com Staff
From Our Partners